iBio, Inc. Common Stock Asset Resilience Ratio
iBio, Inc. Common Stock asset resilience ratio. iBio, Inc. Common Stock (IBIO) has an Asset Resilience Ratio of 31.93% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See iBio, Inc. Common Stock defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of iBio, Inc. Common Stock (2013–2026)
Asset resilience ratio of iBio, Inc. Common Stock from 2013 to 2026. This chart shows how iBio, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read IBIO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down iBio, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see iBio, Inc. Common Stock balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $31.64 Million | 31.93% |
| Total Liquid Assets | $31.64 Million | 31.93% |
Asset Resilience Insights
- Very High Liquidity: iBio, Inc. Common Stock maintains exceptional liquid asset reserves at 31.93% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
iBio, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare iBio, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
iBio, Inc. Common Stock Asset Resilience Ratio by Year (2013–2026)
iBio, Inc. Common Stock asset resilience ratio by year from 2013 to 2026. The table below shows the annual Asset Resilience Ratio data for iBio, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-06-30 | 31.93% | $31.64 Million | $99.11 Million | -- |
| 2025-06-30 | 0.00% | $0.00 | $23.18 Million | -- |
| 2023-06-30 | 0.00% | $0.00 | $41.21 Million | -- |
| 2022-06-30 | 10.91% | $10.85 Million | $99.41 Million | -2.41pp |
| 2021-06-30 | 13.32% | $19.57 Million | $146.97 Million | -- |
| 2020-06-30 | 0.00% | $0.00 | $94.19 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $43.08 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $36.01 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $51.60 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $12.49 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $6.49 Million | -- |
| 2013-06-30 | 0.00% | $0.00 | $9.35 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimiz… Read more